Platinum-induced hearing loss after treatment for childhood cancer

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 8, 2016, Pages

  van As, Jorrit W ^a   van den Berg, Henk ^a   van Dalen, Elvira C ^a  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; PLATINUM; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER SURVIVOR; CHILDHOOD CANCER; HEARING IMPAIRMENT; HIGH RISK PATIENT; HUMAN; OTOTOXICITY; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; ADOLESCENT; CHEMICALLY INDUCED; CHILD; COHORT ANALYSIS; HEARING LOSS; INFANT; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; CISPLATIN; COHORT STUDIES; HEARING LOSS; HUMANS; INFANT; PREVALENCE; RISK FACTORS; YOUNG ADULT;

EID: 84982665617     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010181.pub2     Document Type: Review

References (187)

1. Bertolini P, Lassalle M, Mercier G, Raquin MA, Izzi G, Corradini N, et al. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. Journal of Pediatric Hematology/Oncology 2004;26(10):649-55.
2. Cushing B, Giller R, Cullen JW, Marina NM, Lauer SJ, Olson TA, et al. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study - Pediatric Oncology Group 9049 and Children's Cancer Group 8882. Journal of Clinical Oncology 2004;22(13):2691-700.
3. Hudson MM, Ness KK, Gurney JG, Mulrooney DA, Chemaitilly W, Krull KR, et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA 2013;309(22):2371-81 Erratum in: JAMA (2013);310(1):99.
4. Jehanne M, Lumbroso-Le Rouic L, Savignoni A, Aerts I, Mercier G, Bours D, et al. Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma. Pediatric Blood & Cancer 2009;52(5):637-43.
5. Kennedy C, Bull K, Chevignard M, Culliford D, Dörr HG, Doz F, et al. Quality of survival and growth in children and young adults in the PNET4 European controlled trial of hyperfractionated versus conventional radiation therapy for standard-risk medulloblastoma. International Journal of Radiation Oncology Biology Physics 2014;88(2):292-300.
6. Lambert MP, Shields C, Meadows AT. A retrospective review of hearing in children with retinoblastoma treated with carboplatin-based chemotherapy. Pediatric Blood & Cancer 2008;50(2):223-6.
7. Landier W, Knight K, Wong FL, Lee J, Thomas O, Kim H, et al. Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales - a report from the Children's Oncology Group. Journal of Clinical Oncology 2014;32(6):527-34.
8. Mandell LR, Kadota R, Freeman C, Douglass EC, Fontanesi J, Cohen ME, et al. There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherapy. International Journal of Radiation Oncology, Biology, Physics 1999;43(5):959-64.
9. Peleva E, Emami N, Alzahrani M, Bezdjian A, Gurberg J, Carret AS, et al. Incidence of platinum-induced ototoxicity in pediatric patients in Quebec. Pediatric Blood & Cancer 2014;61(11):2012-7.
10. Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, et al. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. New England Journal of Medicine 2009;361:1662-70.
11. Shields CL, Honavar SG, Meadows AT, Shields JA, Demirci H, Singh A, et al. Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation. American Journal of Ophthalmology 2002;133(5):657-64.
12. Shields CL, Mashayekhi A, Au AK, Czyz C, Leahey A, Meadows AT, et al. The International Classification of Retinoblastoma Predicts Chemoreduction Success. Ophthalmology 2006;113:2276-80.
13. Simon T, Hero B, Dupuis W, Selle B, Berthold F. The incidence of hearing impairment after successful treatment of neuroblastoma. Klinische Padiatrie 2002;214(4):149-52.
14. Aksnes LH, Bauer HCF, Dahl AA, Fossa SD, Hjorth L, Jebsen N, et al. Health status at long-term follow-up in patients treated for extremity localized Ewing sarcoma or osteosarcoma: a Scandinavian Sarcoma Group Study. Pediatric Blood & Cancer 2009;53:84-9.
15. Altaf S, Enders F, Jeavons E, Krailo M, Barkauskas DA, Meyers P, et al. High-BMI at diagnosis is associated with inferior survival in patients with osteosarcoma: a report from the Children's Oncology Group. Pediatric Blood & Cancer 2013;60(12):2042-6.
16. Ansari S, Parhyscar J. Hearing loss in pediatric oncology patients cisplatin regimens. Pediatric Blood & Cancer 2010:1008.
17. Armstrong GT, Conklin H, Huang S, Gajjar A, Merchant TE, Hudson M, et al. Long-term survival & health outcomes after diagnosis of low grade glioma (ii30). International Symposium on Pediatric Neuro-Oncology. 2010.
18. Bacci G, Longhi A, Fagioli F, Briccoli A, Versari M, Picci P (2005). Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. European Journal of Cancer 2005;41:2836-45.
19. Baker DL, Schmidt ML, Cohn SL, Maris JM, London WB, Buxton A, et al. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. New England Journal of Medicine 2010;363:1313-23.
20. Bass JK, Huang J, Onar-Thomas A, Chang KW, Bhagat SP, Chintagumpala M, et al. Concordance between the Chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma. Pediatric Blood & Cancer 2014;61(4):601-5.
21. Batra A, Thakar A, Bakhshi S. Ototoxicity in retinoblastoma survivors treated with carboplatin based chemotherapy: a cross-sectional study of 116 patients. Pediatric Blood & Cancer 2015;62(11):2060.
22. Berthold F, Boos J, Burdach S, Erttmann R, Henze G, Hermann J, et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncology 2005;6:649-58.
23. Bostrom B, Woods WG, Ramsay NK, Krivit W, Levine P, Nesbit ME Jr. Cisplatin, vinblastine, and bleomycin (CVB) therapy for relapsed disseminated neuroblastoma. Cancer Treatment Reports 1984;68(9):1157-8.
24. Bramwell VH, Brugarolas A, Mouridsen HT, Cheix F, de Jager R, van Oosterom AT, et al. E.O.R.T.C. phase II study of cisplatin in cyvadic-resistant soft tissue sarcoma. European Journal of Cancer 1979;15(12):1511-3.
25. Brinkman TM, Bass JK, Li Z, Ness KK, Gajjar A, Pappo AS, et al. Treatment-induced hearing loss and adult social outcomes in survivors of childhood CNS and non-CNS solid tumors: results from the St. Jude Lifetime Cohort Study. Cancer 2015;121(22):4053-61.
26. Brock P, Pritchard J, Bellman S, Pinkerton CR. Ototoxicity of high-dose cis-platinum in children. Medical and Pediatric Oncology 1988;16(5):368-9.
27. Brock PR, Bellman SC, Yeomans EC, Pinkerton CR, Pritchard J. Cisplatin ototoxicity in children: a practical grading system. Medical and Pediatric Oncology 1991;19:295-300.
28. Buckner JC, Ballman KV, Michalak JC, Burton GV, Cascino TL, Schomberg PJ, et al. Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials. Journal of Clinical Oncology 2006;24(24):3871-9.
29. Calvo D, Pat YZ, Wallace S, Hersch EM, Benjamin RS, Pritchard J, et al. Phase I trial of percutaneous intra-arterial (IA) cis-diammine dichloride platinum II (CDDP) for regionally confined malignancies (C-558). Proceedings of the American Association for Cancer Research. 1979.
30. Carleton B, Poole R, Smith M, Leeder J, Ghannadan R, Ross C, et al. Adverse drug reaction active surveillance: developing a national network in Canada's children's hospitals. Pharmacoepidemiology and Drug Safety 2009;18(8):713-21.
31. Carleton BC, Ross CJ, Bhavsar AP, Lee JW, Visscher H, Rassekh SR, et al. Response to "Evaluation of pharmacogenetic markers to predict the risk of cisplatin-induced ototoxicity". Clinical Pharmacology and Therapeutics 2014;96(2):158.
32. Carleton BC, Ross CJ, Bhavsar AP, Amstutz U, Pussegoda K, Visscher H, et al. Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity. Clinical Pharmacology and Therapeutics 2014;95(3):253.
33. Carr BI, Kondragunta V, Buch SC, Branch RA. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer 2010;116:1305-14.
34. Castel V, Badal MD, Bezanilla JL, Llombart A, Ruiz-Jimenez JI, Sanchez de TJ, et al. Treatment of stage III neuroblastoma with emphasis on intensive induction chemotherapy: a report from the Neuroblastoma Group of the Spanish Society of Pediatric Oncology. Medical and Pediatric Oncology 1995;24(1):29-35.
35. Chang KW, Chinosornvatana N. Practical grading system for evaluating cisplatin ototoxicity in children. Journal of Clinical Oncology 2010;28:1788-95.
36. Chantada G, Fandino A, Davila MTG, Manzitti J, Raslawski E, Casak S, et al. Results of a prospective study for the treatment of retinoblastoma. Cancer 2004;100:834-42.
37. Chen CA, Lin H, Weng CS, Wen KC, Lu CH, Chou HH, et al. Outcome of 3-day bleomycin, etoposide and cisplatin chemotherapeutic regimen for patients with malignant ovarian germ cell tumours: a Taiwanese Gynecologic Oncology Group study. European Journal of Cancer 2014;50(18):3161-7.
38. Cohen BH, Zweidler P, Goldwein JW, Molloy J, Packer RJ. Ototoxic effect of cisplatin in children with brain tumors. Pediatric Neurosurgery 1991;16:292-6.
39. Corder MP, Leimert JT, Panther SK, Elliott TE. A phase II study of cis-platinum II diamminedichloride (CPDD) in lymphoma (C-38). Proceedings of the American Association for Cancer Research. 1979.
40. Coze C, Hartmann O, Michon J, Frappaz D, Dusol F, Rubie H, et al. NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: a report from the French Society of Pediatric Oncology. Journal of Clinical Oncology 1997;15(12):3433-40.
41. Diez B, Monges J, Muriel FS. Evaluation of cisplatin in children with recurrent brain tumors. Cancer Treatment Reports 1985;69:911-3.
42. Di Pinto M, Conklin HM, Li C, Merchant TE. Learning and memory following conformal radiation therapy for pediatric craniopharyngioma and low-grade glioma. International Journal of Radiation Oncology Biology Physics 2012;84(3):e363-9.
43. Dominici C, Clerico A, Castello MA. Chemotherapy of regional or metastatic neuroblastoma with high-dose cisplatin by continuous intravenous infusion and etoposide. Rivista Italiana di Pediatria 1989;15:373-8.
44. Einhorn LH, Foster RS. Bleomycin, etoposide, and cisplatin for three cycles compared with etoposide and cisplatin for four cycles in good-risk germ cell tumors: is there a preferred regimen?. Journal of Clinical Oncology 2006;24:2597-98.
45. Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. New England Journal of Medicine 2007;357(4):340-8.
46. Ekhart C, Rodenhuis S, Smits PHM, Beijnen JH, Huitema ADR. Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin. Pharmacogenetics and Genomics 2008;18:1009-15.
47. Ettinger LJ, Gaynon PS, Krailo MD, Ru N, Baum ES, Siegel SE, et al. A phase II study of carboplatin in children with recurrent or progressive solid tumors. A report from the Childrens Cancer Group. Cancer 1994;73(4):1297-301.
48. Flege S, Bielack S. Goal and results of the COSS study. Handchirurgie, Mikrochirurgie, Plastische Chirurgie 2004;36(5):282-8.
49. Fosså SD, de Wit R, Roberts JT, Wilkinson PM, de Mulder PH, Mead GM, et al. Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20). Journal of Clinical Oncology 2003;21(6):1107-18.
50. Fouladi M, Gilger E, Kocak M, Wallace D, Buchanan G, Reeves C, et al. Intellectual and functional outcome of children 3 years old or younger who have CNS malignancies. Journal of Clinical Oncology 2005;23:7152-60.
51. Fox E, Citrin D, Balis FM. The legacy of cancer therapy in children. Journal of the National Cancer Institute 2009;101(16):1105-7.
52. Fuchs N, Bielack SS, Epler D, Bieling P, Delling G, Korholz D, et al. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Annals of Oncology 1998;9:893-99.
53. Fuchs J, Bode U, Schweinitz DV, Weinel P, Erttmann R, Harms D, et al. Analysis of treatment efficiency of carboplatin and etoposide in combination with radical surgery in advanced and recurrent childhood hepatoblastoma: a report of the German cooperative pediatric liver tumor study HB 89 and HB 94. Klinische Padiatrie 1999;211:305-9.
54. Gaynon P, Baum E, Greenberg L, Krivit W, Hammond D, Taylor S. A phase II trial of cis-platinum diammine dichloride (DDP) (NSC 119825) in refractory childhood tumors: a CCSG trial (C-424). Proceedings of the American Association for Cancer Research. 1979.
55. Germà Lluch JR, Izquierdo Font A, Barnadas Molins A, Arcusa Lanza MA, Ojeda González B. Delayed platinum diamminodichloride toxicity in patients with germ tumors of the gonads. Medicina Clinica 1984;82(10):442-5.
56. Gnekow AK, Kortmann RD, Pietsch T, Emser A. Low grade chiasmatic-hypothalamic glioma - carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy: Report from the multicenter treatment study for children and adolescents with a low grade glioma - HIT-LGG 1996 - of the Society of Pediatric Oncology and Hematology (GPOH). Klinische Pädiatrie 2004;216:331-42.
57. Gobel U, Bamberg M, Haas RJ, Bokkerink JPM, Bramswig G, Calaminus G, et al. Non-testicular germ cell tumors: analysis of the MAKEI 83/86 therapy study and protocol changes for the follow-up study. Klinische Padiatrie 1989;201:247-60.
58. Göbel U, Haas RJ, Calaminus G, Bamberg M, Bökkerink EB, Engert J, et al. Treatment of germ cell tumors in children: results of European trials for testicular and non-testicular primary sites. Critical Reviews in Oncology/Hematolology 1990;10(2):89-98.
59. Green DM. Chemotherapy for the treatment of children and adolescents with malignant germ cell tumors. Journal of Clinical Oncology 2008;26(20):3297-8.
60. Grewal S, Merchant T, Reymond R, McInerney M, Hodge C, Shearer P. Auditory late effects of childhood cancer therapy: a report from the Children's Oncology Group. Pediatrics 2010;125(4):e938-50.
61. Grill J, Dufour C, Kalifa C. High-dose chemotherapy in children with newly-diagnosed medulloblastoma. Lancet Oncology 2006;7(10):787-9.
62. Gurney JG, Tersak JM, Ness KK, Landier W, Matthay KK, Schmidt ML. Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: a report from the Children's Oncology Group. Pediatrics 2007;120:e1229-36.
63. Gurney JG, Bass JK, Onar-Thomas A, Huang J, Chintagumpala M, Bouffet E, et al. Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma. Neuro-Oncology 2014;16(6):848-55.
64. Hagleitner MM, Hoogerbrugge PM, van der Graaf WTA, Flucke U, Schreuder HWB, te Loo DMWM. Age as prognostic factor in patients with osteosarcoma. Bone 2011;49:1173-7.
65. Hagleitner MM, de Bont ES, te Loo DM. Survival trends and long-term toxicity in pediatric patients with osteosarcoma. Sarcoma 2012;2012:636405.
66. Hagleitner MM, Coenen MJH, Gelderblom H, Hoogerbrugge P, Guchelaar HJ, te Loo DMWM. Association of the genetic variants in the nucleotide excision repair genes XPA and XPC with cisplatin-induced hearing loss in patients with osteosarcoma (10077). Annual Meeting of the American Society of Clinical Oncology 2012.
67. Hagleitner MM, Coenen MJ, Patino-Garcia A, de Bont ES, Gonzalez-Neira A, Vos HI, et al. Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts. PLoS One 2014;9(12):e115869.
68. Hill JM, Loeb E, MacLellan A, Hill NO, Khan A, King JJ. Clinical studies of platinum coordination compounds in the treatment of various malignant diseases. Cancer Chemotherapy Reports 1975;59(3):647-59.
69. Hishiki T, Matsunaga T, Sasaki F, Yano M, Ida K, Horie H, et al. Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: report from the JPLT. Pediatric Surgery International 2011;27:1-8.
70. Hiyama E, Kamimatsuse A, Kamei N, Watanabe K, Hishiki T, Tajiri T, et al. Outcome of hepatoblastoma treated with the JPLT-2 protocol from the experience of JPLT (Japanese Study Group for Pediatric Liver Tumor) study. Pediatric Blood & Cancer 2010:816.
71. Hiyama E, Kamimatsuse A, Kamei N, Watanabe K, Hishiki T, Tajiri T, et al. Cisplatin plus pirarubicin chemotherapy and combination ifomide, etoposide, pirarubicin, and carboplatin chemotherapy for hepatoblastoma. Annual Meeting of the American Society of Clinical Oncology. 2010.
72. Hiyama E, Ueda Y, Onitake Y, Kurihara S, Watanabe K, Hishiki T, et al. A cisplatin plus pirarubicin-based JPLT2 chemotherapy for hepatoblastoma: experience and future of the Japanese Study Group for Pediatric Liver Tumor (JPLT). Pediatric Surgery International 2013;29(10):1071-5.
73. Hovi L, Wikstrom S, Vettenranta K, Heikkila P, Saarinen-Pihkala UM. Adrenocortical carcinoma in children: a role for etoposide and cisplatin adjuvant therapy? Preliminary report. Medical and Pediatric Oncology 2003;40:324-6.
74. Jakacki RI, Burger PC, Zhou T, Holmes EJ, Kocak M, Onar A, et al. Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: a children's oncology group phase I/II study. Journal of Clinical Oncology 2012;30(21):2648-53.
75. Khan A, McCullough D. Use of cis-platinum in CNS malignancy (C-144). Proceedings of the American Association for Cancer Research. 1979.
76. Kamalakar P, Wang JJ, Higby D, Freeman AI, Wallace HJ. Clinical experience with CIS diammine dichloroplatinum (DDP) in children (C-188). Proceedings of the American Association for Cancer Research. 1976.
77. Kingston JE, Abramovich S, Billings RJ. Assessment of the effect of chemotherapy and radiotherapy on the auditory function of children with cancer. Clinical Otolaryngology and Allied Sciences 1986;11:403-9.
78. Kortmann RD, Kuhl J, Timmermann B, Mittler U, Urban C, Budach V, et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91. International Journal of Radiation Oncology, Biology, Physics 2000;46(2):269-79.
79. Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, et al. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncology 2013;14(10):999-1008.
80. Kremers A, Langer T, Stohr W, Beck JD, Rascher W. Late effects of oncological therapy in children. Padiatrische Praxis 2003;64:47-64.
81. Landier W, Knight KR, Wong FL, Lee JK, Thomas O, Kim H, et al. Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales - a report from the Children's Oncology Group (COG) (abstract number 9515). ASCO Annual Meeting. 2011.
82. Landier W, Armenian SH, Lee J, Thomas O, Wong FL, Francisco L, et al. Yield of screening for long-term complications using the children's oncology group long-term follow-up guidelines. Journal of Clinical Oncology 2012;30(35):4401-8.
83. Lanvers-Kaminsky C, Malath I, Deuster D, Ciarimboli G, Boos J, Am Zehnhoff-Dinnesen AG. Evaluation of pharmacogenetic markers to predict the risk of cisplatin-induced ototoxicity. Clinical Pharmacology and Therapeutics 2014;96(2):156-7.
84. Laverdiere C, Liu Q, Yasui Y, Nathan PC, Gurney JG, Stovall M, et al. Long-term outcomes in survivors of neuroblastoma: a report from the childhood cancer survivor study. Journal of the National Cancer Institute 2009;101:1131-40.
85. Le Deley MC, Guinebretière JM, Gentet JC, Pacquement H, Pichon F, Marec-Bérard P, et al. SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. European Journal of Cancer 2007;43(4):752-61.
86. Lewis IJ, Stevens MC, Pearson AD, Pinkerton CR, Barnes JM. Carboplatin activity in cisplatin treated neuroblastoma. Advances in Neuroblastoma Research 1991;366:553-9.
87. Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PCW, et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. Journal of the National Cancer Institute 2007;99:112-28.
88. Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. European Journal of Cancer 2004;40(16):2445-51.
89. Lippman AJ, Helson C, Helson L, Krakoff IH. Clinical trials of cis-diamminedichloroplatinum (NSC-119875). Cancer Chemotherapy Reports Part 1 1973;57(2):191-200.
90. Liu W, Tang Y, Gao L, Huang X, Luo J, Zhang S, et al. Nasopharyngeal carcinoma in children and adolescents - a single institution experience of 158 patients. Radiation Oncology 2014;9:274.
91. Mahoney DH Jr, Weaver T, Steuber CP, Starling KA. Cis-platinum (CDDP) ototoxicity in pediatric patients. Proceedings of the American Society of Clinical Oncology. 1982.
92. Mahoney DH Jr, Weaver T, Steuber CP, Starling KA. Ototoxicity with cisplatin therapy. Journal of Pediatrics 1983;103(6):1006-7.
93. Manfredini L, Garaventa A, Barra S, de Caro E, Picco P, Faraci M, et al. Health status of long term survivors after myeloablative therapy and bone marrow transplantation in children. Bone Marrow Transplantation 1996;18 Suppl 2:163-4.
94. Mann JR, Raafat F, Robinson K, Imeson J, Gornall P, Sokal M, et al. The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity. Journal of Clinical Oncology 2000;18(22):3809-18.
95. Marshall NE, Ballman KV, Michalak JC, Schomberg PJ, Burton GV, Sandler HM, et al. Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patients. Journal of Neuro-Oncology 2006;77(3):315-20.
96. Mbue JE, Solimando DA Jr, Waddell JA. Doxorubicin, cisplatin, high-dose methotrexate, and ifosfamide for osteosarcoma. Hospital Pharmacy 2007;42:801-15.
97. McHaney VA, Thibadoux G, Hayes FA, Green AA. Hearing loss in children receiving cisplatin chemotherapy. Journal of Pediatrics 1983;102(2):314-7.
98. Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. Journal of Clinical Oncology 2005;23:2004-11.
99. Montero A, Hervas A, Morera R, Sancho S, Cordoba S, Corona JA, et al. Control of chronic symptoms. Secondary effects of treatments with radiotherapy and chemotherapy. Oncologia 2005;28:41-50.
100. Nageswara RAA, Wallace D, Boyett J, Gajjar A, Packer RJ. Cumulative cisplatin dose (CCD) does not correlate with event free (EFS) and overall survival (OS) outcomes in children with newly diagnosed average-risk medulloblastoma (ARMB) treated with cisplatin based adjuvant chemotherapy. Annals of Neurology Conference. 2011:S118-9.
101. Nageswara Rao AA, Wallace D, Boyett J, Gajjar A, Packer RJ. Cumulative cisplatin dose does not correlate with event-free and overall survival outcomes in children with newly diagnosed average-risk medulloblastoma treated with cisplatin-based adjuvant chemotherapy (PC-07). Annual Scientific Meeting of the Society for Neuro-Oncology. 2011:iii96.
102. Nageswara Rao AA, Wallace DJ, Billups C, Boyett JM, Gajjar A, Packer RJ. Cumulative cisplatin dose is not associated with event-free or overall survival in children with newly diagnosed average-risk medulloblastoma treated with cisplatin based adjuvant chemotherapy: report from the Children's Oncology Group. Pediatric Blood & Cancer 2014;61(1):102-6.
103. Nichols CR, Williams SD, Loehrer PJ, Greco FA, Crawford ED, Weetlaufer J, et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. Journal of Clinical Oncology 1991;9(7):1163-72.
104. Packer RJ, Sutton LN, Goldwein JW, Perilongo G, Bunin G, Ryan J, et al. Improved survival with the use of adjuvant chemotherapy in the treatment of medulloblastoma. Journal of Neurosurgery 1991;74:433-40.
105. Packer RJ, Gajjar A, Vezina G, Rorke-Adams L, Burger PC, Robertson PL, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. Journal of Clinical Oncology 2006;24:4202-8.
106. Pearson AD, Pinkerton CR, Lewis IJ, Imeson J, Ellershaw C, Machin D. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncology 2008;9:247-56.
107. Pendergrass TW, Milstein JM, Geyer JR, Mulne AF, Kosnik EJ, Morris JD, et al. Eight drugs in one day chemotherapy for brain tumors: experience in 107 children and rationale for preradiation chemotherapy. Journal of Clinical Oncology 1987;5(8):1221-31.
108. Perilongo G, Shafford E, Maibach R, Aronson D, Brugières L, Brock P, et al. Risk-adapted treatment for childhood hepatoblastoma. final report of the second study of the International Society of Paediatric Oncology-SIOPEL 2. European Journal of Cancer 2004;40(3):411-21.
109. Pritchard J, Brown J, Shafford E, Perilongo G, Brock P, Dicks-Mireaux C, et al. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach - results of the first prospective study of the International Society of Pediatric Oncology. Journal of Clinical Oncology 2000;18:3819-28.
110. Punyko JA, Mertens AC, Gurney JG, Yasui Y, Donaldson SS, Rodeberg DA, et al. Long-term medical effects of childhood and adolescent rhabdomyosarcoma: a report from the childhood cancer survivor study. Pediatric Blood & Cancer 2005;44:643-53.
111. Pussegoda K, Ross CJ, Visscher H, Yazdanpanah M, Brooks B, Rassekh SR, et al. Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. Clinical Pharmacology and Therapeutics 2013;94(2):243-51.
112. Raney RB, Asmar L, Vassilopoulou-Sellin R, Klein MJ, Donaldson SS, Green J, et al. Late complications of therapy in 213 children with localized, nonorbital soft-tissue sarcoma of the head and neck: a descriptive report from the Intergroup Rhabdomyosarcoma Studies (IRS)-II and - III. IRS Group of the Children's Cancer Group and the Pediatric Oncology Group. Medical and Pediatric Oncology 1999;33(4):362-71.
113. Rassekh R, Ross C, Brooks B, Katzov H, Dube MP, Carleton B, et al. Identification of genetic markers of severe hearing loss in children receiving cisplatin. Pediatric Blood & Cancer 2009:733.
114. Rednam S, Scheurer M, Adesina A, Lau C, Okcu M. Glutathione s-transferase P1 single nucleotide polymorphism predicts permanent ototoxicity in children with medulloblastoma (i125). International Symposium on Pediatric Neuro-Oncology. 2012.
115. Rednam S, Scheurer ME, Adesina A, Lau CC, Okcu MF. Glutathione S-transferase P1 single nucleotide polymorphism predicts permanent ototoxicity in children with medulloblastoma. Pediatric Blood & Cancer 2013;60(4):593-8.
116. Roark KM, Waddell JA, Solimando DA Jr. Bleomycin, etoposide, and cisplatin (BEP) regimen for testicular cancer. Hospital Pharmacy 2003;38:638-44.
117. Rosen EM, Cassady JR, Frantz CN. Improved survival in neuroblastoma using multimodality therapy. Radiotherapy and Oncology 1984;2:189-200.
118. Ross CJ, Katzov-Eckert H, Dubé MP, Brooks B, Rassekh SR, Barhdadi A, et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nature Genetics 2009;41(12):1345-9.
119. Rutledge MR, Solimando DA Jr, Waddell JA. Doxorubicin and cisplatin regimen for high-grade osteosarcoma or malignant fibrous histiocytoma (MFH) of the bone. Hospital Pharmacy 2007;42:605-16.
120. Sanz MA, Bonanad S, Sanz GF, Martín G. Carboplatin and etoposide in acute myeloid leukemia. Leukemia 1994;8(9):1599-600.
121. Sawaguchi S, Kaneko M, Uchino J, Takeda T, Iwafuchi M, Matsuyama S, et al. Treatment of advanced neuroblastoma with emphasis on intensive induction chemotherapy. A report from the Study Group of Japan. Cancer 1990;66(9):1879-87.
122. Sawamura Y, Ikeda J, Shirato H, Tada M, Abe H. Germ cell tumours of the central nervous system: treatment consideration based on 111 cases and their long-term clinical outcomes. European Journal of Cancer 1998;34:104-10.
123. Schell MJ, McHaney VA, Green AA, Kun LE, Hayes FA, Horowitz M, et al. Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. Journal of Clinical Oncology 1989;7(6):754-60.
124. Schreiber JE, Gurney JG, Palmer SL, Bass JK, Wang M, Chen S, et al. Examination of risk factors for intellectual and academic outcomes following treatment for pediatric medulloblastoma. Neuro-Oncology 2014;16(8):1129-36.
125. Sefi E, Brock P, Chang K, Neuwelt E, Knight K, Rajput K. Validation of the SIOP Boston ototoxicity scale - an international scale for the evaluation of platinum-induced ototoxicity in children (P-0486). Pediatric Blood & Cancer. 2013:167.
126. Singh Chauhan R, Saxena RK, Varshey S. The role of ultrahigh-frequency audiometry in the early detection of systemic drug-induced hearing loss. Ear Nose & Throat Journal 2011;90(5):218-22.
127. Soomal R, Saran F, Brada M. In regard to Huang et al.: intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity. IJROBP 2002;52:599-605. International Journal of Radiation Oncology Biology Physics 2003;55(3):853.
128. Souhami RL, Craft AW, van der Eijken JW, Nooij M, Spooner D, Bramwell VHC, et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 1997;350:911-7.
129. Spracklen TF, Whitehorn H, Vorster AA, Ramma L, Dalvie S, Ramesar RS. Genetic variation in Otos is associated with cisplatin-induced ototoxicity. Pharmacogenomics 2014;15(13):1667-76.
130. Steinherz P, Tan C, Ghavimi F, Helson L, Rosen G, Wollner N. VAB III combination chemotherapy in childhood malignancies (C-231). Proceedings of the American Association for Cancer Research. 1977.
131. Stewart D, Wallace S, Leavens M. Phase I study of intracarotid (IC) cis-diamminedichloroplatinum (DDP) in patients with intracerebral tumors (ICT). Proceedings of the American Association for Cancer Research. 1981; Vol. 22:749.
132. Suita S, Zaizen Y, Kaneko M, Uchino J, Takeda T, Iwafuchi M, et al. What is the benefit of aggressive chemotherapy for advanced neuroblastoma with N-myc amplification? A report from the Japanese study group for the treatment of advanced neuroblastoma. Journal of Pediatric Surgery 1994;29:746-50.
133. Tseng A Jr, Jacobs C, Coleman CN, Horning SJ, Lewis BJ, Rosenberg SA. Treatment of refractory non-Hodgkin's lymphomas of unfavorable histology with teniposide, cytarabine, and cisplatin. Cancer Treatment Reports 1987;71:659-60.
134. Umeda T, Takada N, Hodaka E. Toxic effects of cisplatin in treatment of malignant bone and soft tissue tumors. Japanese Journal of Cancer and Chemotherapy 1986;13:1857-61.
135. Van Maldegem AM, Benson C, Rutkowski P, Blay JY, van den Berg H, Placzke J, et al. Etoposide and carbo- or cisplatin combination therapy in refractory or relapsed Ewing sarcoma: a large retrospective study. Pediatric Blood & Cancer 2015;62(1):40-4.
136. Veal GJ, Boddy AV. Carboplatin dosing in infants with retinoblastoma: a case for therapeutic drug monitoring. Journal of Clinical Oncology 2012;30(27):3424.
137. Von Heyden HW, Scherpe A, Nagel GA. Cis-dichlorodiammineplatinum (II) (cis-platinum) and etoposide for patients with refractory lymphomas. Cancer Treatment Reviews 1982;9:45-52.
138. Von Hoff K, Hinkes B, Gerber NU, Deinlein F, Mittler U, Urban C, et al. Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT'91. European Journal of Cancer 2009;45:1209-17.
139. Voskens C, Cavallaro A, Erdmann M, Dippel O, Kaempgen E, Schuler G, et al. Anti-cytotoxic T-cell lymphocyte antigen-4-induced regression of spinal cord metastases in association with renal failure, atypical pneumonia, vision loss, and hearing loss. Journal of Clinical Oncology 2012;30(33):e356-7.
140. Whelan K, Stratton K, Kawashima T, Leisenring W, Hayashi S, Waterbor J, et al. Auditory complications in childhood cancer survivors: a report from the childhood cancer survivor study. Pediatric Blood & Cancer 2011;57(1):126-34.
141. Whitehorn H, Sibanda M, Lacerda M, Spracklen T, Ramma L, Dalvie S, et al. High prevalence of cisplatin-induced ototoxicity in Cape Town, South Africa. South African Medical Journal 2014;104(4):288-91.
142. Winkler K, Bielack S, Delling G, Salzer-Kuntschik M, Kotz R, Greenshaw C, et al. Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS-86). Cancer 1990;66(8):1703-10.
143. Winkler K, Bielack SS, Delling G, Jurgens H, Kotz R, Salzer-Kuntschik M. Treatment of osteosarcoma: experience of the Cooperative Osteosarcoma Study Group (COSS). Cancer Treatment and Research 1993;62:269-77.
144. Xu H, Robinson GW, Huang J, Lim JY, Zhang H, Bass JK, et al. Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. Nature Genetics 2015;47(3):263-6.
145. Yancey A, Harris M, Egbelakin A, Gilbert J, Pisoni D, Renbarger J. Gender is a predictor of cisplatin ototoxicity. Pediatric Blood & Cancer 2010:851.
146. Yancey A, Harris MS, Egbelakin A, Gilbert J, Pisoni DB, Renbarger J. Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients. Pediatric Blood & Cancer 2012;59(1):144-8.
147. Yang JJ, Lim JY, Huang J, Bass J, Wu J, Wang C, et al. The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Clinical Pharmacology and Therapeutics 2013;94(2):252-9.
148. Zage PE, Kletzel M, Murray K, Marcus R, Castleberry R, Zhang Y, et al. Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the children's oncology group. Pediatric Blood & Cancer 2008;51:747-53.
149. Baum ES, Gaynon P, Greenberg L, Krivit W, Hammond D. Phase II trial of cisplatin in refractory childhood cancer: Children's Cancer Study Group Report. Cancer Treatment Reports 1981;65(9-10):815-22.
150. Clemens E, de Vries AC, van Dulmen-den Broeder E, van Grotel M, Pluijm SF, Tissing WJ, et al. The influence of co-medication on platinum-related ototoxicity in long-term survivors of childhood cancer: a descriptive DCOG study. 14th International Conference on Long-Term Complications of Treatment of Children and Adolescents for Cancer. 2015:69 (abstract 111).
151. Clerico A, Robert M, Marucci G, D'Attilia FR, Dionne V, Pecoraro R, et al. Preirradiation carboplatin and etoposide in the treatment of paediatric medulloblastoma in a single institution. Pediatric Blood & Cancer 2010:1005.
152. Finlay JL, Haley K, Dhall G, Fangusaro J, Chi S, Allen J, et al. Management of young children newly diagnosed with CNS embryonal tumors: 18 years of three sequential irradiation-avoiding chemotherapy studies - The "Head Start" protocols. Neuro-Oncology Conference 2009:875-6.
153. Geyer JR, Sposto R, Jennings M, Boyett JM, Axtell RA, Breiger D, et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. Journal of Clinical Oncology 2005;23:7621-31.
154. Hiyama E, Kamimatsuse A, Onitake Y, Ueda Y, Watanabe K, Hishiki T, et al. Survival, surgical resectability, and late effects in the hepatoblastoma patients treated by cisplatin plus pirarubicin (CITA) chemotherapy (10038). Annual Meeting of the American Society of Clinical Oncology 2013.
155. Knight K, Middaugh J, Fu R, Neuwelt E, Winter C. Long term audiologic outcomes in children treated with platinum chemotherapy. Pediatric Blood & Cancer 2014:S196.
156. Korzeniewska J, Dembowska-Baginska B, Drogosiewicz M, Perek-Polnik M, Perek D. Sensory status of childhood brain tumors survivors (PQ.002). Pediatric Blood & Cancer 2009:853.
157. Kuhl J, Muller HL, Berthold F, Kortmann RD, Deinlein F, Maass E, et al. Preradiation chemotherapy of children and young adults with malignant brain tumors: results of the German pilot trial HIT'88/'89. Klinische Padiatrie 1998;210(4):227-33.
158. Kushner BH, Budnick A, Kramer K, Modak S, Cheung NK. Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer 2006;107(2):417-22.
159. Lannering B, Rutkowski S, Doz F, Pizer B, Gustafsson G, Navajas A, et al. Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. Journal of Clinical Oncology 2012;30(26):3187-93.
160. Merchant TE, Hua C, Bass JK, Wu S, Xiong X, Gajjar A. The impact of ototoxic chemotherapy on hearing loss after radiation therapy in children with brain tumors. International Journal of Radiation Oncology, Biology, Physics 2011:S113-4.
161. Nirenberg A, Cacavio A, Bru G, Gaparros B, Rosen G. Ambulatory high dose cisplatinum (HD-DDP) with mannitol diuresis: a treatment system without renal, auditory or biochemical toxicity C-766. Proceedings of the American Association for Cancer Research. 1981.
162. Ohnuma N, Takahashi H, Kaneko M, Uchino J-I, Takeda T, Iwafuchi M, et al. Treatment combined with bone marrow transplantation for advanced neuroblastoma: an analysis of patients who were pretreated intensively with the protocol of the study group of Japan. Medical and Pediatric Oncology 1995;24:181-7.
163. Vos HI, Coenen MJ, Gelderblom H, van der Straaten T, de Bont ES, van der Graaf WT, et al. Association of genetic variants involved in drug metabolism and transport with efficacy and toxicity of chemotherapeutic treatment in osteosarcoma patients. Journal of Clinical Oncology 2014;32: 5s:abstract 10038.
164. Weiss A, Kasteler R, Kuonen R, Wengenroth L, Scheinemann K, Grotzer M, et al. Hearing impairment in Swiss childhood cancer survivors. 14th International Conference on Long-Term Complications of Treatment of Children and Adolescents for Cancer. 2015:69-70 (abstract 112).
165. Bass JK, Bhagat SP. Challenges in ototoxicity monitoring in the pediatric oncology population. Journal of the American Academy of Audiology 2014;25(8):760-74.
166. Jenney MEM. Late effects of cancer treatment and current protective measures. In: Voûte PA, Barett A, Stevens MCG, Caron HN editor(s). Cancer in Children. 5th Edition. Oxford: Oxford University Press, 2005:123-37.
167. Dean JB, Hayashi SS, Albert CM, King AA, Karzon R, Hayashi RJ. Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens. Journal of Pediatric Hematology/Oncology 2008;30(2):130-4.
168. Eloxatin Summary of Product Characteristics. www.sanofi-aventis.co.uk/products/Eloxatin_SPC.pdf (accessed 2 March 2010).
169. Gallagher KL, Jones JK. Furosemide-induced ototoxicity. Annals of Internal Medicine 1979;91(1):744-5.
170. Gietema JA, Meinardi MT, Messerschmidt J, Gelevert T, Alt F, Uges DR, et al. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet 2000;355(9209):1075-6.
171. Gregg RB, Wiorek LS, Arvedson JC. Pediatric audiology: a review. Pediatrics in Review 2004;25(7):224-33.
172. Grimes DA, Schulz KF. Cohort studies: marching towards outcomes. Lancet 2002;359(9303):341-5.
173. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
174. Kadota RP, Mandell LR, Fontanesi J, Kovnar EH, Krischer J, Kun LE, et al. Hyperfractionated irradiation and concurrent cisplatin in brain stem tumors: a Pediatric Oncology Group pilot study (9139). Pediatric Neurosurgery 1994;20(4):221-5.
175. Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. Journal of Clinical Oncology 2005;23(34):8588-96.
176. Laupacis A, Wells G, Richardson WS, Tugwell P. Users' guides to the medical literature. V. How to use an article about prognosis. Evidence-Based Medicine Working Group. JAMA 1994;272(3):234-7.
177. Leahey A. A cautionary tale: dosing chemotherapy in infants with retinoblastoma. Journal of Clinical Oncology 2012;30(10):1023-4.
178. National Health Service. Hearing loss - causes. www.nhs.uk/Conditions/hearing-impairment/Pages/causes.aspx (accessed 18 July 2016).
179. Qaddoumi I, Bass JK, Wu J, Billups CA, Wozniak AW, Merchant TE, et al. Carboplatin-associated ototoxicity in children with retinoblastoma. Journal of Clinical Oncology 2012;30(10):1034-41.
180. Reddel RR, Kefford RF, Grant JM, Coates AS, Fox RM, Tattersall MH. Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. Cancer Treatment Reports 1982;66(1):19-23.
181. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
182. Skinner R. Best practice in assessing ototoxicity in children with cancer. European Journal of Cancer 2004;40(16):2352-4.
183. Van As JW, van den Berg H, van Dalen EC. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD009219.pub2]
184. Van As JW, van den Berg H, van Dalen EC. Different infusion durations for preventing platinum-induced hearing loss in children with cancer. Cochrane Database of Systematic Reviews 2014, Issue 6. [DOI: 10.1002/14651858.CD010885.pub2]
185. van As JW, van den Berg H, van Dalen EC. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD009219.pub3]
186. Veal GJ, Dias C, Price L, Parry A, Errington J, Hale J, et al. Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy. Clinical Cancer Research 2001;7(8):2205-12.
187. Van As JW, van den Berg H, van Dalen EC. Platinum-induced hearing loss after treatment for childhood cancer. Cochrane Database of Systematic Reviews 2012, Issue 11. [DOI: 10.1002/14651858.CD010181]